Drug Trial Radar · NCT02058160
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes
Last checked: Nov 20, 2026Latest source record: May 9, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
736
Actual
Start
Jan 2014
Primary completion
Jul 2015
Study completion Jul 2015
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Feb 7, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: To demonstrate the superiority of the insulin glargine/lixisenatide fixed ratio combination (FRC) to insulin glargine in glycated hemoglobin (HbA1c) change from baseline to Week 30. Secondary Objective: To compare the overall efficacy and safety of insulin glargine/lixisenatide FRC to insulin glargine (with or without metformin) over a 30 week treatment period in participants with type 2 diabetes.
Conditions
- Type 2 Diabetes
Interventions
Insulin glargine/lixisenatide (HOE901/AVE0010)Drug
Insulin glargine/lixisenatide FRC was self-administered by subcutaneous (SC) injection within 1 hour before breakfast using one of 2 SoloStar® pen-injectors: Pen A (ratio of 2 Units (U) of insulin glargine U 100:1 mcg of lixisenatide) or Pen B (ratio of 3 U of insulin glargine U 100:1 mcg of lixisenatide). After run-in, the FRC was initiated at a dose of either 20 U/10 mcg with Pen A or 30 U/10 mcg with Pen B, depending on participant's dose of Insulin glargine on the day prior to randomization. Dose was adjusted weekly to reach and maintain fasting self-monitored plasma glucose (SMPG) of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L). Pen A was used for administration of doses up to 40 U/20 mcg and Pen B for administration of doses from 30 U/10 mcg up to 60 U/20 mcg.
Insulin glargine (HOE901)Drug
Insulin glargine was self-administered QD by SC injection at approximately the same time every day. After screening, eligible participants entered 6 week run-in phase during which they were switched (if necessary) to insulin glargine and dose was stabilized. The first dose after randomization was same as the one administered on the day prior to randomization and then dose was adjusted weekly to reach and maintain fasting SMPG of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L).
Metformin (Background Drug)Drug
Pharmaceutical form: Tablet; Route of administration: Oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Glycated Hemoglobin (HbA1c) From Baseline to Week 30Time frame: Baseline, Week 30
Locations
236 sites in 18 countries. Site status is shown where the registry gives one.
Investigational Site Number 840607
Birmingham, Alabama
Investigational Site Number 840570
Sun City, Arizona
Investigational Site Number 840562
Tempe, Arizona
Investigational Site Number 840577
Tucson, Arizona
Investigational Site Number 840517
Little Rock, Arkansas
Investigational Site Number 840537
Little Rock, Arkansas
Investigational Site Number 840568
Bell Gardens, California
Investigational Site Number 840550
Chino, California
Investigational Site Number 840529
Chula Vista, California
Investigational Site Number 840623
Corona, California
Investigational Site Number 840566
Fresno, California
Investigational Site Number 840552
Greenbrae, California
Investigational Site Number 840578
Lancaster, California
Investigational Site Number 840626
Los Angeles, California
Investigational Site Number 840581
Los Angeles, California
Investigational Site Number 840621
Mission Viejo, California
Investigational Site Number 840511
Northridge, California
Investigational Site Number 840573
Palm Springs, California
Investigational Site Number 840559
Port Hueneme, California
Investigational Site Number 840536
San Ramon, California
Investigational Site Number 840567
Santa Ana, California
Investigational Site Number 840569
Tarzana, California
Investigational Site Number 840572
West Hills, California
Investigational Site Number 840582
Aurora, Colorado
Investigational Site Number 840509
Denver, Colorado
Investigational Site Number 840549
Wilmington, Delaware
Investigational Site Number 840510
Miami, Florida
Investigational Site Number 840521
New Port Richey, Florida
Investigational Site Number 840602
Ocala, Florida
Investigational Site Number 840538
Ocoee, Florida
Investigational Site Number 840534
Palm Harbor, Florida
Investigational Site Number 840594
Atlanta, Georgia
Investigational Site Number 840614
Columbus, Georgia
Investigational Site Number 840501
Lawrenceville, Georgia
Investigational Site Number 840525
Roswell, Georgia
Investigational Site Number 840588
Idaho Falls, Idaho
Investigational Site Number 840580
Arlington Heights, Illinois
Investigational Site Number 840519
Chicago, Illinois
Investigational Site Number 840612
Chicago, Illinois
Investigational Site Number 840556
Springfield, Illinois
Showing 40 of 236 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.